Culture Biosciences will use new funding to increase bioreactor capacity and create additional monitoring software.
The San Francisco contract development and manufacturing organization (CDMO) announced the completion of a $15 million (€13.4 million) series A financing round this week, explaining it had attracted support from new venture capital backers as well as existing investors.
Culture Biosciences said it will use the cash to triple bioreactor capacity and to create additional cloud-based biomanufacturing R&D software monitoring and development tools.
Image: iStock/yekorzh
CEO Will Patrick said, “This funding will support our goal of making biomanufacturing R&D a digital experience by enabling scientists to manage their entire R&D workflow in our software application.â€
Self-facilitating culture media node
In non tech-speak, “making biomanufacturing R&D a digital experience†translates roughly as using computers to make bioprocess R&D more efficient.
Culture Biosciences has a software platform and bioreactor set up that allows biopharmaceutical developers to run, analyze and monitor scale-up experiments in real time without needing to be present.
The advantage – according to the firm – is that real-time monitoring lets bioprocess scientists carry out multiple studies in parallel, meaning they “can spend more time designing and analyzing experiments.â€
“This scale-up process is bottlenecked by legacy approaches to fermentation, which require companies to either build in-house fermentation facilities or contract an outside lab to run their experiments.
“Both approaches are limited in speed, flexibility and convenience, contributing to lengthy lab-to-market timelines that can stretch well beyond five years and cost companies hundreds of millions of dollars in R&D expenses,†Culture Biosciences wrote earlier this year.
X Factor
Culture Biosciences was founded by former engineers from X, Google’s “semi-secret†technology R&D arm.
In February, Culture Biosciences completed a $5.5 million funding round. It used the proceeds to quintuple bioreactor capacity at its facility in South San Francisco.
The firm claims it has a 30-strong client base that includes both biotech start-up and large biopharma companies. It also works with the wider biomanufacturing sector.
Culture Biosciences also says it has recently expanded it capabilities to include mammalian cell culture development R&D.